Neupro

PreclinicalSmall molecule

UCB

Neupro is one of 61 small molecule programs targeting Restless Legs Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Restless Legs SyndromeUnknown

Parkinson DiseaseUnknown

Restless Legs SyndromePreclinical

Unknown

Parkinson DiseasePreclinical

Unknown

Competition

Competitive Landscape

91 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Northera

Lundbeck

Approved

1 2

Myrbetriq

Astellas

Approved

1 3

Medrol

Pfizer

Approved

1 4

Brintellix

Takeda

Approved

1 5

Dostinex

Golytely

Buspar

Cymbalta

Intropin

Neupro

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

Completed· UCB logo

UCB··NCT01330290·148 enrolled

Parkinson's Disease1 trial

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

Completed· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 1·NCT02055274·39 enrolled

Restless Legs Syndrome1 trial

Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

Completed· UCB logo

UCB··NCT01113710·687 enrolled

MPA1 trial

Adhesion and Safety of Rotigexole Compared to Neupro®

Not yet recruiting·EEva Pharma·N/A·NCT07015346·40 enrolled

Single Dose1 trial

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Terminated· Novartis logo

Novartis·Phase 1·NCT04183634·31 enrolled

1 more indication

Unspecified1 trial

The Practical Effect of Neupro

Unknown status·PPeking University Third Hospital··NCT04957420·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Neupro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neupro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neupro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UCB

Neupro

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Parkinson's Disease1 trial

Restless Legs Syndrome1 trial

MPA1 trial

Single Dose1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News